Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα

Blood

Volumn 92, Issue 4, 1998, Pages 1334-1341

  Ling, Weijun ^a   Rayman, Patricia ^a   Uzzo, Robert ^a   Clark, Peter ^a   Kim, Hyung Jin ^a   Tubbs, Raymond ^a   Novick, Andrew ^a   Bukowski, Ronald ^a   Hamilton, Thomas ^a   Finke, James ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; RELB PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ARTICLE; DNA BINDING; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; CELL NUCLEUS; CULTURE MEDIUM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING; T LYMPHOCYTE SUBPOPULATION; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CARCINOMA, RENAL CELL; CELL NUCLEUS; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-REL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0032528628     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1334     Document Type: Article

References (65)

1. Altman A, Coggeshall K, Mustelin T: Molecular events mediating T cell activation. Adv Immunol 48:227, 1990
2. Ullman KS, Northrop JP, Verweij CL, Crabtree GR: Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: The missing link. Annu Rev Immunol 8:421, 1990
3. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705, 1986
4. Nolan GP, Baltimore D: The inhibitory ankyrin and activator Rel proteins. Curr Opin Genet Dev 2:211, 1992
5. Ghosh S, Gifford AM, Riviere LR, Tempst P, Noland GP, Balitmore D: Cloning of the p50 DNA binding subunit of NFκB: Homology to rel and dorsal. Cell 62:1019, 1990
6. Ruben SM, Dillon PJ, Schreck R, Henkel T, Cohen CH, Maher M, Baeurele PA, Rosen CA: Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NFκB. Science 254:11, 1991
7. Kieran M, Blank V, Logeat F, Vandekerckhove J, Lottspeich F, Le Bail O, Urban MB, Kourilsky P, Baeurle PA, Israel A: The DNA binding subunit of NFκB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 62:1007, 1990
8. Noland GP, Ghosh S, Liou HC, Tfempst P, Baltimore D: DNA binding and IκB inhibition of the cloned p65 subunit of NFκB, a rel-related polypeptide. Cell 64:961, 1991
9. Brownell E, Mittereder N, Rice NR: A human rel proto-oncogene cDNA containing an Alu fragment as a potential coding exon. Oncogene 4:935, 1989
10. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RS, Dalla-Favera R: B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 67:1075, 1991
11. Schmid RM, Perkins ND, Duckett CS, Andrews PC, Nabel GJ: Cloning of an NFκB subunit which stimulates HIV transcription in synergy with p65. Nature 352:733, 1991
12. Ryseck RP, Bull P, Takamrya M, Bours V, Siebenlist U, Dobrzanski P, Bravo R: RelB, a new Rel family transcription activator that can interact with p50-NFκB. Mol Cell Biol 12:674, 1992
13. Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck RP, Bravo R, Kelly K, Siebenlist U: A novel mitogen-inducible gene product related to p50/p105-NFκB participates in transactivation through a κB site. Mol Cell Biol 12:685, 1992
14. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F: A novel complex between the p65 subunit of NF-κB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11:205, 1992
15. Urban MB, Schreck R, Baeuerle PA: NF-κB contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J 10:1817, 1991
16. + T lymphocytes. Science 256:1452, 1992
17. Gilmore TD, Morin PJ: The IκB proteins: Members of a multifunctional family. Trends Genet 9:427, 1993
18. Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD, Sampson-Johannes A, Mondal K, Ralph P, Baldwin AS Jr: Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 65:1281, 1991
19. Beg AA, Baldwin AS Jr: The I kappa B proteins: Multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev 7:2064, 1993
20. Thanos D, Maniatis T: NFκB: A lesson in family values. Cell 80:529, 1995
21. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA: Rapid proteolysis of IκBα is necessary for activation of transcription factor NFκB. Nature 365:182, 1993
22. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW: Coupling of signal response domain in IκBα to multiple pathways for NFκB activation. Mol Cell Biol 15:2809, 1995
23. Traenckner, EB-M, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA: Phosphorylation of human IκBα on serines 32 and 36 controls IκBα proteolysis and NFκB activation in response to diverse stimuli. EMBO J 14:2876, 1995
24. Hersh EM, Oppenheim JJ: Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med 273:1006, 1965
25. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370, 1991
26. Miescher S, Whiteside TL, Carrel S, Von Fliedner V: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899, 1986
27. + T cells. J Immunol 149:949, 1992
28. Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, Nomoto K: Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52:775, 1992
29. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH: T-cell infiltrating renal cell carcinoma display a poor proliferative response even though they can produce IL-2 and express IL2 receptors. Cancer Res 53:1380, 1993
30. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Von Fliedner V: Proliferative and cytolytic potentials of purified human tumor-in filtrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 42:659, 1988
31. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795, 1992
32. Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS: Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL2 secreting tumors. J Immunol 153:5176, 1994
33. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R: Decreased expression of the signal-transducing Ζ chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610, 1993
34. lck in T-cell infiltrating human renal cell carcinoma. Cancer Res 53:5613, 1993
35. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327, 1995
36. Kono K, Ressing ME, Brandt RMP, Melief CJM, Potkul RK, Anderson B, Petersson M, Kast WM, Kiessling R: Decreased expression of signal-transducing Ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825, 1996
37. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH: Variable expression of CD3-Ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function. Int J Cancer 63:205, 1995
38. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL: Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2:1263, 1996
39. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Kromschlies KL: Alterations in NFκB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969, 1994
40. Li X, Liu J, Park J-K, Hamilton TA, Rayman P, Klein E, Edinger M, Tubbs R, Bukowski R, Finke J: T cells from renal cell carcinoma patients exhibit an abnormal pattern of κB-specific DNA binding activity, a preliminary report. Cancer Res 54:5424, 1994
41. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478, 1995
42. Wang Q, Stanley J, Kudoh S, Myles J, Kolenko V, Yi T, Tubbs R, Bukowski R, Finke J: T Cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol 155: 1382, 1995
43. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res 7:6419, 1989
44. Rice NR, Ernst MK: In vivo control of NF-κB activation by IκBα.EMBOJ 12:4685, 1993
45. Naumann M, Scheidereit C: Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J 13:4597, 1994
46. Brown K, Park S, Kanno T, Franzoso T, Siebenlist U: Mutual regulation of the transcriptional activator NFκB and its inhibitor, IκBα. Proc Natl Acad Sci USA 90:2532, 1993
47. Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y: In vivo stimulation of IκB phosphorylation is not sufficient to activate NFκB. Mol Cell Biol 15:1294, 1995
48. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM: Tumor necrosis factor α-induced phosphorylation of IκBα is a signal for its degradation but not dissociation from NFκB. Proc Natl Acad Sci USA 91:12740, 1994
49. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr: Tumor necrosis factor and interleukin 1 lead to phosphorylation and loss of IκBα: A mechanism for NFκB activation. Mol Cell Biol 13:3301, 1993
50. Molitor JA, Walker WH, Doerre D, Ballard DW, Greene WC: NF-κB: A family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci USA 87:10028, 1990
51. Arima N, Kuziel WA. Grdina TA, Greene WC: IL-2-induced signal transduction involves the activation of nuclear NF-κB expression. J Immunol 149:83, 1992
52. Granelli-Piperno A, Nolon P: Nuclear transcription factors that bind to elements of the IL2 promoter. Induction requirements in primary human T cells. J Immunol 147:2734, 1991
53. Costello R, Lipcey C, Algarte M, Cerdan C, Baeuerle PA, Olive D, Imbert J: Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NFκB. Cell Growth Differ 4:329, 1993
54. Lowenthal JW, Ballard DW, Bohnlein E, Greene WC: Tumor necrosis factor α induces proteins that bind specifically to κB-like enhancer elements and regulate interleukin-2 receptor α-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci USA 86:2331, 1989
55. Ghosh S, Baltimore D: Activation in vitro of NFκB by phosphorylation of its inhibitor IκB. Nature 344:678, 1990
56. Diaz-Meco MT, Dominguez I, Sanz L, Dent P, Lozano J, Municio MM, Berra E, Hay RT, Sturgill TW, Moscat J: ζPKC induced phosphorylation and inactivation of IκBα in vitro. EMBO J 13:2842, 1994
57. Finco TS, Baldwin AS Jr: KB site-dependent induction of gene expression by diverse inducers of nuclear factor kB requires Raf-1. J Biol Chem 268:17676, 1993
58. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, Williams BR, Aguet M, Weissman C: Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 14:6095, 1995
59. Lee FS, Hagler J, Chen ZJ, Maniatis T: Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88:213, 1997
60. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M: A cytokine-responsive IκB kinase that activates the transcription factor NFκB. Nature 388:548, 1997
61. Aoe T, Okamoto Y, Saito T: Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881, 1995
62. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and NK-mediated cytotoxicity. Eur J Immunol 26:1308, 1996
63. Guarini A, Riera L, Cignetti A, Montacchini L, Massaia M, Foa R: Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 89:212, 1997
64. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J: Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL2 receptor signaling: Role of soluble products from human renal cell carcinomas. J Immunol 159:3057, 1997
65. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, Bukowski RM: Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes. Intl J Cancer 61:780, 1995